New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)

Ocio, E M; Richardson, P G; Rajkumar, S V; Palumbo, A; Mateos, M V; Orlowski, R; Kumar, S; Usmani, S; Roodman, D; Niesvizky, R; Einsele, H; Anderson, K C; Dimopoulos, M A; Avet-Loiseau, H; Mellqvist, U-H; Turesson, I; Merlini, G; Schots, R; McCarthy, P; Bergsagel, L
March 2014
Leukemia (08876924);Mar2014, Vol. 28 Issue 3, p525
Academic Journal
Treatment in medical oncology is gradually shifting from the use of nonspecific chemotherapeutic agents toward an era of novel targeted therapy in which drugs and their combinations target specific aspects of the biology of tumor cells. Multiple myeloma (MM) has become one of the best examples in this regard, reflected in the identification of new pathogenic mechanisms, together with the development of novel drugs that are being explored from the preclinical setting to the early phases of clinical development. We review the biological rationale for the use of the most important new agents for treating MM and summarize their clinical activity in an increasingly busy field. First, we discuss data from already approved and active agents (including second- and third-generation proteasome inhibitors (PIs), immunomodulatory agents and alkylators). Next, we focus on agents with novel mechanisms of action, such as monoclonal antibodies (MoAbs), cell cycle-specific drugs, deacetylase inhibitors, agents acting on the unfolded protein response, signaling transduction pathway inhibitors and kinase inhibitors. Among this plethora of new agents or mechanisms, some are specially promising: anti-CD38 MoAb, such as daratumumab, are the first antibodies with clinical activity as single agents in MM. Moreover, the kinesin spindle protein inhibitor Arry-520 is effective in monotherapy as well as in combination with dexamethasone in heavily pretreated patients. Immunotherapy against MM is also being explored, and probably the most attractive example of this approach is the combination of the anti-CS1 MoAb elotuzumab with lenalidomide and dexamethasone, which has produced exciting results in the relapsed/refractory setting.


Related Articles

  • Myeloma kidney: advances in molecular mechanisms of acute kidney injury open novel therapeutic opportunities. Davenport, Andrew; Merlini, Giampaolo // Nephrology Dialysis Transplantation;Oct2012, Vol. 27 Issue 10, p3713 

    Renal impairment is a common complication of multiple myeloma (MM) and is supported in virtually all patients by a tubulointerstitial pathology that results from high serum concentrations of monoclonal free light chains (FLCs). The proteins involved in the kidney injury and the analysis of their...

  • Immunotherapy in multiple myeloma: Id-specific strategies suggested by studies in animal models. Corthay, Alexandre; Lundin, Katrin U.; Munthe, Ludvig A.; Frøyland, Marianne; Gedde-Dahl, Tobias; Dembic, Zlatko; Bogen, Bjarne // Cancer Immunology, Immunotherapy;Sep2004, Vol. 53 Issue 9, p759 

    Multiple myeloma (MM) cells produce monoclonal immunoglobulin (Ig) which serves as a truly tumor-specific antigen. The tumor-specific antigenic determinants are localized in the variable (V)-regions of the monoclonal Ig and are called idiotopes (Id). We review here the evidence obtained in a...

  • Extravasation of Yttrium-90 Ibritumomab Tiuxetan: A Case Study. Siebeneck, Bettina M. // Clinical Journal of Oncology Nursing;Apr2008, Vol. 12 Issue 2, p275 

    Ibritumomab tiuxetan is a radiolabled monoclonal antibody that targets B-cell non-Hodgkin lymphoma tumor cells. Yttrium-90 (Y-90), the radioisotope used to deliver the therapy, may act as a vesicant, potentially causing severe tissue damage if extravasation occurs. Particularly important to...

  • MielominÄ— liga: klinikinis atvejis. Matyženok, U.; Gelažiūtė, S.; Gleiznys, D. // Neurologijos Seminarai;2012, Vol. 16 Issue 2, p152 

    Multiple myeloma is a malignant hematologic disorder characterized by proliferation of clonal plasma cells and over production of monoclonal immunoglobulins. Diagnosis of this disease is based on standardized criteria, including plasma cell infiltration of bone marrow, osteolytic bone lesions,...

  • Multiple myeloma in a murine syngeneic model:modulation of growth and angiogenesis by a monoclonal antibody to kininogen. Sainz, Irma M.; Isordia-Salas, Irma; Espinola, Ricardo G.; Long, Walter K.; Pixley, Robin A.; Colman, Robert W. // Cancer Immunology, Immunotherapy;Jul2006, Vol. 55 Issue 7, p797 

    Multiple myeloma (MM), a B-cell malignancy characterized by proliferation of monoclonal plasma cells remains incurable. Murine plasma cell tumors share common features with human MM. We used two cell lines (B38 and C11C1) derived from P3X63Ag8 myeloma cells. The new cell lines were implanted...

  • Characterization of the Infrared Spectra of Serum from Patients with Multiple Myeloma. Plotnikova, L.; Polyanichko, A.; Nosenko, T.; Uspenskaya, M.; Garifullin, A.; Voloshin, S. // AIP Conference Proceedings;2016, Vol. 1760 Issue 1, p1 

    Multiple myeloma (MM) accounts for about 1% of all types of cancers. MM is characterized by the proliferation of a single clone of plasma cells, which may produce and secrete a homogeneous monoclonal immunoglobulin. The monoclonal immunoglobulin is commonly referred to as an M protein. The M...

  • Elotuzumab: a new monoclonal antibody for multiple myeloma therapy. Staderini, Michela; Nozzoli, Chiara // Drugs & Cell Therapies in Hematology;2016, Issue 1, p68 

    For decades, since its first description, multiple myeloma represented a hard challenge for clinicians due to the scarce results obtained with conventional chemotherapies. Autologous stem cells transplantation and novel drugs such as immunomodulating drugs (IMIDs) and proteasome inhibitors (PIs)...

  • Profile of elotuzumab and its potential in the treatment of multiple myeloma. Yi-Chang Liu; Szmania, Susann; van Rhee, Frits // Blood & Lymphatic Cancer: Targets & Therapy;2014, Vol. 4, p15 

    Although the introduction of novel drugs has improved outcome significantly in multiple myeloma (MM), many patients still eventually relapse. Monoclonal antibodies (mAbs) targeting MM-related antigens can complement currently available therapies. CS1 (also known as CD2 subunit 1, SLAMF7, CD319,...

  • A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. de Vos, Sven; Forero-Torres, Andres; Ansell, Stephen M.; Kahl, Brad; Cheson, Bruce D.; Bartlett, Nancy L.; Furman, Richard R.; Winter, Jane N.; Kaplan, Henry; Timmerman, John; Whiting, Nancy C.; Drachman, Jonathan G.; Advani, Ranjana // Journal of Hematology & Oncology;2014, Vol. 7 Issue 1, p3 

    Background Patients with DLBCL who are ineligible for or have relapsed after aggressive salvage chemotherapy have a poor prognosis. CD40 is expressed on multiple B-cell neoplasms including DLBCL and is a potential target for immunotherapy. Dacetuzumab (SGN-40), a non-blocking, partial agonist,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics